Amphibian myocardial angiotensin II receptors are distinct from mammalian AT1 and AT2 receptor subtypes.
High-affinity receptors for angiotensin II were identified on Xenopus laevis cardiac membranes and characterized by binding-inhibition studies with peptide and non-peptide AII antagonists. Scatchard analysis of the binding data identified a high-affinity site with Kd1 = 1.6 nM and Bmax1 = 3.7 pmol/mg protein and a low-affinity site with Kd2 = 22 nM and Bmax 2 = 9.5 pmol/mg protein. Treatment with dithiothreitol reduced the number of binding sites by greater than 70%. The rank order of potency for ALL analogs was (agent, IC50) [Sar1,Ile8]AII, 0.91 nM greater than AII, 2.0 nM greater than AI, 5.3 nM greater than [Sar1, Ala8]AII, 19 nM much greater than CGP42112A, 1.2 microM much much greater than DuP 753 approximately PD-123177, greater than 100 microM. The relative potencies of these compounds differ markedly from their activities on the two known mammalian AII receptor subtypes, AT1 and AT2. These results indicate that amphibian AII receptors are pharmacologically distinct from both the AT1 and AT2 receptors characterized in mammalian tissues.
Sandberg
K
K
Endocrinology and Reproduction Research Branch, National Institutes of Child Health and Human Development, NIH, Bethesda, MD 20892.
Ji
H
H
Millan
M A
MA
Catt
K J
KJ
D015059:1-Sarcosine-8-Isoleucine Angiotensin II / Q000378:metabolism; D000803:Angiotensin I / Q000378:metabolism; D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D001667:Binding, Competitive; D002462:Cell Membrane / Q000378:metabolism; D004229:Dithiothreitol / Q000494:pharmacology; D007700:Kinetics; D009206:Myocardium / Q000378:metabolism*; D009865:Oocytes / Q000378:metabolism; D011945:Receptors, Angiotensin / Q000378:metabolism*; D012504:Saralasin / Q000378:metabolism; D014982:Xenopus laevis / Q000378:metabolism*
D011945:Receptors, Angiotensin; D000804:Angiotensin II; D000803:Angiotensin I; D015059:1-Sarcosine-8-Isoleucine Angiotensin II; D012504:Saralasin; D004229:Dithiothreitol